Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
11 01 2022
11 01 2022
Historique:
received:
06
04
2021
accepted:
05
07
2021
pubmed:
22
9
2021
medline:
11
3
2022
entrez:
21
9
2021
Statut:
ppublish
Résumé
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.
Identifiants
pubmed: 34547770
pii: 476983
doi: 10.1182/bloodadvances.2021004916
pmc: PMC8753217
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
339-357Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130388
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215134
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI128775
Pays : United States
Informations de copyright
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):319-26
pubmed: 24548609
J Hematol Oncol. 2020 Mar 30;13(1):27
pubmed: 32228710
Blood Adv. 2019 Nov 12;3(21):3351-3359
pubmed: 31698447
Eur J Haematol. 2018 May;100(5):395-402
pubmed: 29360184
Blood Adv. 2020 May 12;4(9):2073-2083
pubmed: 32396617
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Blood. 2015 Aug 20;126(8):1033-40
pubmed: 26130705
Biol Blood Marrow Transplant. 2016 Nov;22(11):1983-1987
pubmed: 27492792
Int J Cancer. 2015 Apr 1;136(7):1697-707
pubmed: 25138425
Cancer. 2017 Sep 1;123(17):3346-3355
pubmed: 28452054
J Hematol Oncol. 2020 May 6;13(1):46
pubmed: 32375860
Leuk Lymphoma. 2015 May;56(5):1362-9
pubmed: 25139689
Haematologica. 2012 Oct;97(10):1523-31
pubmed: 22491731
Br J Haematol. 2014 Jun;165(5):688-98
pubmed: 24588540
Biol Blood Marrow Transplant. 2020 Oct;26(10):1861-1867
pubmed: 32629157
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Leukemia. 2012 Nov;26(11):2367-74
pubmed: 22705993
J Clin Oncol. 2021 Feb 1;39(4):295-307
pubmed: 33332189
Blood Cells Mol Dis. 2004 Nov-Dec;33(3):281-7
pubmed: 15528145
J Hematol Oncol. 2013 Feb 06;6:14
pubmed: 23388549
J Hematol Oncol. 2017 May 30;10(1):113
pubmed: 28558762
Haematologica. 2019 Mar;104(3):524-532
pubmed: 30361416
Biol Blood Marrow Transplant. 2019 Nov;25(11):2113-2123
pubmed: 31446198
Br J Haematol. 2017 Oct;179(1):120-130
pubmed: 28737249
Am J Hematol. 2019 May;94(5):512-521
pubmed: 30680765
Bone Marrow Transplant. 2013 Mar;48(3):396-402
pubmed: 22858507
Blood Adv. 2019 Jun 25;3(12):1826-1836
pubmed: 31201170
Blood. 2021 Jan 21;137(3):420-428
pubmed: 33475736
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Bone Marrow Transplant. 2013 Jul;48(7):908-14
pubmed: 23708705
Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58
pubmed: 18541193
Biol Blood Marrow Transplant. 2018 Apr;24(4):726-733
pubmed: 29197676
Blood. 2008 Feb 15;111(4):1827-33
pubmed: 18048644
Biol Blood Marrow Transplant. 2012 Jun;18(6):963-8
pubmed: 22430088
J Hematol Oncol. 2020 May 15;13(1):52
pubmed: 32414392
Clin Cancer Res. 2016 Jul 15;22(14):3467-76
pubmed: 26927664
Biol Blood Marrow Transplant. 2014 Sep;20(9):1307-13
pubmed: 24769317
Blood. 2016 Mar 17;127(11):1502-8
pubmed: 26764356
Cochrane Database Syst Rev. 2011 Oct 05;(10):CD008818
pubmed: 21975786
Blood. 2015 Apr 16;125(16):2486-96; quiz 2586
pubmed: 25587040
Haematologica. 2021 Jun 01;106(6):1591-1598
pubmed: 32354866
Blood. 2013 Jan 10;121(2):339-50
pubmed: 23165481
Biol Blood Marrow Transplant. 2017 Feb;23(2):318-324
pubmed: 27856368
Blood Adv. 2019 Feb 26;3(4):670-680
pubmed: 30808685
Bone Marrow Transplant. 2018 Jun;53(6):756-763
pubmed: 29523888
Leukemia. 2020 Jan;34(1):283-292
pubmed: 31427719